OralParenteralTopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Acetylcysteine

CAS 616-91-1

Acetylcysteine (CAS 616-91-1) is a Phase 4 pharmaceutical compound with 5 bioactivity targets and 3,000 adverse event associations.

SOURCE NLM DailyMed
Label records
1
SOURCE EMBL-EBI ChEMBL
Bioactivity
9
SOURCE DrugCentral
Adverse signals
3,000
SOURCE IUPHAR/BPS
PubMed IDs
3
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Acetylcysteine
CAS Number
616-91-1
UNII
WYQ7N0BPYC
InChIKey
PWKSKIMOESPYIA-BYPYZUCNSA-N
ChEMBL ID
CHEMBL600
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
Acetadote
dosed ingredientnatural productoralparenteraltherapeutic flagtopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL600 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE NLM DailyMed 1 label row

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

ProductIngredient Active MoietyEffective
Acetylcysteine Acetylcysteine
WYQ7N0BPYC
 Acetylcysteine 20260506
SOURCE EMBL-EBI ChEMBL 9 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 27989.937974683544 nM 79 -
- Potency 17725.89230769231 nM 36 -
- IC50 35330.524 nM 4 -
- EC50 27950 nM 2 -
Cytochrome c
Enzyme
 - - - Homo sapiens
Vascular endothelial growth factor A
Secreted
 - - - Homo sapiens
Superoxide dismutase [Mn], mitochondrial
Enzyme
 - - - Homo sapiens
Glutathione synthetase
Enzyme
 MODULATOR - - Homo sapiens
Cystine/glutamate transporter
Transporter
 MODULATOR - - Homo sapiens
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Toxic epidermal necrolysis 148 207.072 10044223
Congenital hiatus hernia 43 178.325 10010501
Body tinea 49 162.683 10005913
Stevens-Johnson syndrome 122 158.035 10042033
Chronic obstructive pulmonary disease 169 137.469 10009033
Acute kidney injury 440 135.381 10069339
Infection susceptibility increased 51 133.941 10021866
Inhibitory drug interaction 51 130.068 10068071
Pneumonia 540 122.326 10035664
Glucose tolerance impaired 53 100.163 10018429
Respiratory failure 194 84.791 10038695
Oral herpes 75 83.067 10067152
Dyspnoea 575 81.669 10013968
Productive cough 128 81.428 10036790
Malignant melanoma in situ 31 80.767 10025652
Impaired quality of life 58 78.915 10076936
Bone density decreased 55 77.419 10049470
Breath sounds abnormal 55 76.99 10064780
Joint swelling 17 75.15 10023232
Metabolic acidosis 113 74.899 10027417
Bronchiectasis 63 74.677 10006445
Acute hepatic failure 70 70.553 10000804
Anaphylactoid reaction 36 69.65 10002216
Arthralgia 82 69.573 10003239
Benign prostatic hyperplasia 47 68.211 10004446
Poor quality sleep 62 67.574 10062519
Purpura 54 65.201 10037549
Rheumatoid arthritis 11 61.769 10039073
Drug intolerance 23 60.804 10061822
Arthropathy 8 60.236 10003285
Systemic lupus erythematosus 4 57.383 10042945
Impaired work ability 52 55.59 10052302
Product dose omission issue 21 53.027 10084406
Pain 141 52.643 10033371
Hyperlipidaemia 58 52.348 10062060
General physical health deterioration 221 52.161 10049438
Hepatotoxicity 78 47.933 10019851
Treatment failure 13 46.479 10066901
Tongue oedema 29 45.415 10043967
Abdominal discomfort 35 45.172 10000059
Musculoskeletal stiffness 11 42.77 10052904
Skin disorder 60 42.258 10040831
Brain oedema 47 41.303 10048962
Bronchospasm 47 40.785 10006482
Therapeutic product effect decreased 13 39.613 10082201
Anion gap 17 39.251 10002522
Full blood count abnormal 63 39.025 10017412
Pyrexia 402 38.82 10037660
Acute respiratory failure 70 38.526 10001053
Glossodynia 8 38.332 10018388

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE PharmGKB 7 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

EPHX1 (PA27829) EPHX1 poor metabolizer
EPHX1 poor metabolizer is associated with increased response to acetylcysteine in people with Pulmonary Disease, Chronic Obstructive as compared to genotype fast/normal (assigned as intermediate metabolizer and normal metabolizer phenotype) .
Evidence: -; PMID 25999707
TOLLIP (PA134876213) rs3750920
Genotype TT is associated with increased response to acetylcysteine in people with Pulmonary Fibrosis as compared to genotypes CC + CT.
Evidence: -; PMID 26331942
TOLLIP (PA134876213) rs5743854
Genotype CC is not associated with response to acetylcysteine in people with Pulmonary Fibrosis as compared to genotypes CG + GG.
Evidence: -; PMID 26331942
TOLLIP (PA134876213) rs5743890
Genotype TT is not associated with response to acetylcysteine in people with Pulmonary Fibrosis as compared to genotypes CC + CT.
Evidence: -; PMID 26331942
TOLLIP (PA134876213) rs5743894
Genotype TT is not associated with response to acetylcysteine in people with Pulmonary Fibrosis as compared to genotypes CC + CT.
Evidence: -; PMID 26331942
MUC5B (PA31321) rs35705950
Genotype TT is not associated with response to acetylcysteine in people with Pulmonary Fibrosis as compared to genotypes GG + GT.
Evidence: -; PMID 26331942
TOLLIP rs3750920
Pulmonary Fibrosis
Evidence: 3; PMID 1
SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
acetylcysteine 197 SU MTHSPL
ACETYLCYSTEINE 197 SU MTHSPL
Acetylcysteine 197 SU MTHSPL
acetylcysteine 197 IN RXNORM
Acetadote 404825 BN RXNORM
SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Anaphylactic shock N-acetylcysteine LLT C0002792
Anaphylactic shock N-acetylcysteine PT C0002792
Anaphylactic shock N-acetylcysteine PT C0002792
Anaphylactoid reaction N-acetylcysteine LLT C0340865
Anaphylactoid reaction N-acetylcysteine PT C0340865
Angioedema N-acetylcysteine LLT C0002994
Angioedema N-acetylcysteine PT C0002994
Angiopathy N-acetylcysteine LLT C0042373
Angiopathy N-acetylcysteine PT C0042373
Asthma N-acetylcysteine LLT C0004096
Asthma N-acetylcysteine PT C0004096
Body temperature increased N-acetylcysteine LLT C0015967
Body temperature increased N-acetylcysteine PT C0015967
Bronchoconstriction N-acetylcysteine LLT C0079043
Bronchospasm N-acetylcysteine PT C0006266
Cardiac disorder N-acetylcysteine LLT C0018799
Cardiac disorder N-acetylcysteine PT C0018799
Chest discomfort N-acetylcysteine PT C0235710
Chest tightness N-acetylcysteine LLT C0232292
Cold sweat N-acetylcysteine PT C0232431
Cough N-acetylcysteine LLT C0010200
Cough N-acetylcysteine PT C0010200
Dermatitis N-acetylcysteine PT C0011603
Dizziness N-acetylcysteine PT C0012833
Drowsiness N-acetylcysteine LLT C0013144
Dyspepsia N-acetylcysteine LLT C0013395
Dyspepsia N-acetylcysteine PT C0013395
Dysphoria N-acetylcysteine LLT C0233477
Dysphoria N-acetylcysteine PT C0233477
Dyspnoea N-acetylcysteine LLT C0013404
Dyspnoea N-acetylcysteine PT C0013404
Ear and labyrinth disorders N-acetylcysteine - C0851354
Ear pain N-acetylcysteine LLT C0013456
Ear pain N-acetylcysteine PT C0013456
Erythema N-acetylcysteine PT C0041834
Erythema facial N-acetylcysteine LLT C0239488
Eye pain N-acetylcysteine LLT C0151827
Eye pain N-acetylcysteine PT C0151827
Face oedema N-acetylcysteine LLT C0542571
Face oedema N-acetylcysteine PT C0542571
Feeling hot N-acetylcysteine LLT C2939147
Feeling hot N-acetylcysteine PT C2939147
Flushing N-acetylcysteine LLT C0016382
Flushing N-acetylcysteine PT C0016382
Gait disturbance N-acetylcysteine LLT C0575081
Gait disturbance N-acetylcysteine PT C0575081
Gastrointestinal disorder N-acetylcysteine LLT C0017178
Gastrointestinal disorder N-acetylcysteine PT C0017178
Gastrointestinal disorder N-acetylcysteine PT C0017178
Gastrointestinal symptom NOS N-acetylcysteine LLT C0426576
Haemoptysis N-acetylcysteine LLT C0019079
Haemoptysis N-acetylcysteine PT C0019079
Hyperhidrosis N-acetylcysteine PT C0020458
Hypersensitivity N-acetylcysteine LLT C0020517
Hypersensitivity N-acetylcysteine PT C0020517
Hypotension N-acetylcysteine LLT C0020649
Hypotension N-acetylcysteine PT C0020649
Immune system disorder N-acetylcysteine LLT C0021053
Immune system disorder N-acetylcysteine PT C0021053
Loss of consciousness N-acetylcysteine PT C0041657
Mediastinal disorder N-acetylcysteine LLT C0025061
Mediastinal disorder N-acetylcysteine PT C0025061
Mental disability N-acetylcysteine PT C1306341
Nasopharyngitis N-acetylcysteine PT C0027441
Nausea N-acetylcysteine LLT C0027497
Nausea N-acetylcysteine PT C0027497
Oedema N-acetylcysteine LLT C0013604
Oedema N-acetylcysteine PT C0013604
Palmar erythema N-acetylcysteine LLT C0014745
Palmar erythema N-acetylcysteine PT C0014745
Pharyngitis N-acetylcysteine LLT C0031350
Pharyngitis N-acetylcysteine PT C0031350
Pruritus N-acetylcysteine LLT C0033774
Pruritus N-acetylcysteine PT C0033774
Rash N-acetylcysteine LLT C0015230
Rash N-acetylcysteine PT C0015230
Respiratory distress N-acetylcysteine LLT C0476273
Respiratory distress N-acetylcysteine PT C0476273
Rhinorrhoea N-acetylcysteine LLT C1260880
Rhinorrhoea N-acetylcysteine PT C1260880
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Acetylcysteine used for in pharmaceutical contexts?

Acetylcysteine (CAS 616-91-1) appears in DailyMed active-ingredient label rows, including Acetylcysteine.

What are the known adverse events for Acetylcysteine?

Acetylcysteine has 3,000 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Toxic epidermal necrolysis, Congenital hiatus hernia, Body tinea, Stevens-Johnson syndrome, Chronic obstructive pulmonary disease. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Acetylcysteine also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for ACETYL CYSTEINE with EU status "permitted".

What clinical phase is Acetylcysteine in?

Acetylcysteine is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Acetylcysteine?

Acetylcysteine has 9 bioactivity rows in this page query. Rendered target entries include Cytochrome c, Vascular endothelial growth factor A, Superoxide dismutase [Mn], mitochondrial, Glutathione synthetase, Cystine/glutamate transporter.